FPT and Cymotive Form Strategic Alliance to Advance Automotive Cybersecurity Innovation
HANOI, Vietnam, June 03, 2025--(BUSINESS WIRE)--Global IT services provider FPT has signed a Memorandum of Understanding (MOU) with Cymotive Technologies, an Israel-based leader in automotive cybersecurity. This agreement initiates a collaboration to introduce Cymotive's proven cybersecurity solutions to FPT's established automotive customer base, jointly develop and deliver next-generation cybersecurity solutions for Software-Defined Vehicles (SDVs), and advance safer, smarter, and more connected mobility.
The MOU lays the groundwork for a strategic collaboration focused on the joint development and commercialization of advanced cybersecurity solutions tailored to the evolving demands of the automotive industry. The agreement focuses on leveraging and commercializing Cymotive's pioneering cybersecurity solutions, extensive engineering experience, and deep industry expertise within FPT's global partner network and presence.
The partnership will advance new solutions tailored to evolving automotive market demands and emerging SDV platforms. Both sides aim to maximize end-to-end protection, fully addressing the complex technical and regulatory demands faced by automotive manufacturers and suppliers worldwide.
Nguyen Duc Kinh, FPT Software Executive Vice President and FPT Automotive Chief Executive Officer, FPT Corporation, emphasized the strategic significance of this agreement: "The automotive industry is undergoing a fundamental shift toward software-defined, intelligent mobility. This evolution demands not only robust cybersecurity but also a forward-looking approach to digital resilience at scale. Our partnership with Cymotive enhances our capacity to lead in this transformation, combining trusted cybersecurity expertise with global delivery capabilities to shape a future where secure, autonomous, and connected vehicles are the new standard in mobility."
Cymotive Co-founder, Tamir Bechor, added: "Together, FPT and Cymotive critically accelerate the global growth of cybersecurity connected mobility. The partnership pairs the niche expertise and impressive track records of FPT in driving digital transformation and Cymotive in elevating automotive cybersecurity, positioning us to jointly fortify vehicle safety, steer SDV innovation progress, and stay ahead of ever-evolving cyber threats."
Automotive is among FPT's five strategic directions. Leveraging its two decades of expertise in automotive technology, FPT launched a dedicated subsidiary focusing on automotive technologies in 2023. The company currently boasts a global network of 5,000 automotive software engineers and alliances with top chipmakers, tier-1 suppliers, and OEMs. Its delivery excellence is supported by adherence to international standards and certifications, including ISO/SAE 21434, ISO 26262, A-SIL (A/B/C/D), TiSAX, and A-SPICE Level 3.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam's position on the global tech map and delivering world-class solutions for global enterprises, the Corporation focuses on five strategic areas: Artificial Intelligence, Automotive, Semiconductor, Digital Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit https://fptsoftware.com/
About Cymotive Technologies
Cymotive Technologies is a global automotive cybersecurity provider specializing in preemptive, holistic solutions for vehicles, fleets, and smart mobility. Founded in 2016 and driven by a team of elite cybersecurity specialists, Cymotive empowers manufacturers, suppliers, and automotive technology with continuous in-vehicle and cloud protection and homologation compliance support for software defined vehicles. From top tier cybersecurity engineering services and consultancy to ongoing vulnerability management and regulation compliance, automated intrusion detection, incident response, and security testing, Cymotive manages the evolving SDV attack surface and threat landscape for the entire vehicle lifecycle.
To learn more about Cymotive's comprehensive automotive cybersecurity solutions, visit https://www.cymotive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602304961/en/
Contacts
Media Contact Mai Duong (Ms.)FPT CorporationFPT Software PR ManagerMCP.PR@fpt.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous. ITM-91/ITM-94 is a first-in-class, peptide-based theranostic pair combining the radiotherapeutic compound ITM-91 (Debio 0228) ([177Lu]Lu-DPI-4452), with the diagnostic agent ITM-94 (Debio 0328) ([68Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CAIX). CAIX is a cell surface protein that plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion and metastasis. In September 2024, ITM gained the exclusive worldwide license from Debiopharm for the development and commercial rights of ITM-91/ITM-94. The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement. In the now initiated Part D of the trial, ITM-94 is being evaluated for its effectiveness to accurately classify an indeterminate renal mass as ccRCC or non-cancerous, when compared to CT/MRI imaging and histopathology. Secondary endpoints include sensitivity, specificity, and the positive and predictive value of ITM-94 PET/CT imaging compared to histopathology. This study arm is expected to enroll approximately 36 patients at around 15 clinical sites across the EU, US and Australia. ' The early results from the Gallium-68 CAIX PET/CT diagnostic are remarkable to date. I believe ITM-94 has the potential to change the way urologists and oncologists diagnose and stage patients with clear cell renal cell carcinoma, improving accuracy and reducing the need for biopsies. I have not seen a tracer with a similar profile since the PSMA PET/CT was established,' added Prof. Michael Hofman, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter MacCallum Cancer Centre, Melbourne, Australia. ' Clear cell renal cell carcinoma is the most common form of kidney cancer, with more than 90% of cases overexpressing the CAIX encoding gene. As survival rates are highly dependent on the stage of progression, rapid and precise diagnosis is essential to provide patients with the best possible treatment options and therapeutic outcomes. ITM-94 has already demonstrated potential exceptional imaging qualities, including high tumor-to-background ratios and detecting lesions not visible by CT scan with a potential favorable safety profile. We look forward to exploring the full potential of the theranostic pair ITM-91/ITM-94 across this trial to characterize and treat CAIX expressing cancer cells, advancing the efficacy of targeted radiopharmaceutical therapies,' said Dr. Celine Wilke, Chief Medical Officer of ITM. ' With high-quality imaging and high tumor uptake, ITM-94 has already demonstrated potentially significant diagnostic capabilities in solid tumors. The data gathered in Part D of the trial will be instrumental to the further validation of this theranostic pair. We highly value our partnership with ITM, which will continue to advance the rapid progression of these novel radio-diagnostics and -therapeutics through the clinic,' said Angela Zubel, Chief Development Officer, Research & Development at Debiopharm. About the Phase 1/2 ITM-91/ITM-94 Trial The five-part clinical trial (NCT05706129) is designed to assess the safety and tolerability, imaging characteristics, and efficacy of the theranostic pair ITM-91/ITM-94 in patients with unresectable, locally advanced or metastatic solid tumors. In Part A of the trial, ITM-94 demonstrated exceptional tumor imaging characteristics, with a high tumor-to-background ratio and a favorable tolerability profile in patients with confirmed ccRCC, with results published in the Journal of Nuclear Medicine. Part B, which is ongoing, is assessing escalating doses of the therapeutic agent, ITM-91, in patients whose tumors show high uptake of the imaging tracer. Based on the recommended dose from Part B, Part C of the trial will assess the safety and preliminary efficacy of ITM-91 in patients with ccRCC, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma and potentially other tumor types. In addition to the newly initiated Part D, Part E will assess ITM-94 uptake in other tumors. ITM will assume full sponsorship of the program from Debiopharm once the transfer is completed. About ITM-91/ITM-94 (Debio 0228/ 0328) ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM. ITM-94 ([68Ga]Ga-DPI-4452) is a PET imaging agent that may be used independently and is designed to identify patients whose cancers overexpress CAIX. Once identified, these patients may be treated with the lutetium-labelled radioligand, ITM-91 ([177Lu]Lu-DPI-4452), which delivers targeted radiation to the tumor with the aim to destroy it from the inside. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit We are on X. Follow us @DebiopharmNews at or on LinkedIn. ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected] Debiopharm Contact Dawn Bonine - Head of Communications [email protected] Tel: +41 (0)21 321 01 11 Attachment
Yahoo
an hour ago
- Yahoo
Crude Oil Prices Volatile as U.S. Enters Iran-Israel Conflict
Crude oil prices turned volatile early on Monday after the U.S. joined the Iran-Israel conflict by b Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq futures rise, oil falls as markets reverse course after US strikes on Iran
US stock futures turned higher on Monday, with oil prices paring gains as markets grew cautiously optimistic over Iran's next move after the US entered the Middle East conflict at the weekend. Futures tied to the S&P 500 (ES=F) climbed 0.3%, while those on the tech-heavy Nasdaq (NQ=F) rose roughly 0.4%. Dow Jones Industrial Average futures (YM=F) edged up 0.1%. Stocks are reversing course after President Trump's decision to join Israel's attacks on Iran threw a fresh bout of uncertainty into the market. Futures on the major US gauges initially retreated, while oil jumped over 4% as investors rushed to grapple with the aftereffects of the weekend strikes. "Markets appear to be treating the US strikes on Iran as a contained event for now, rather than the start of a broader war. The muted haven flows suggest investors are still assuming this is a one-off escalation, not a disruption to global oil supply or trade," Saxo strategist Charu Chanana told Reuters. Trump said late Saturday that the US had struck Iran's three main nuclear enrichment facilities, claiming the sites had been "totally obliterated" — a claim that has since been questioned. He threatened Iran with more attacks if the country did not quickly seek peace talks. The focus now is on Iran's next step — both militarily and diplomatically. Its foreign minister on Sunday said it reserves "all options," while its parliament has reportedly voted to block the Strait of Hormuz — though Iran's leaders have yet to make a final decision. The spike in crude prices is now unwinding as jitters about disruption to energy supplies ease. Experts are skeptical that Iran will follow through on its threat to close the waterway, through which around one-fifth of global oil and gas flows. Brent crude (BZ=F) futures pulled back on Monday, trading at near $77 a barrel after jumping over $80 after the US strikes. US benchmark WTI crude futures (CL=F) also lost hold of gains, slipping to below $74 a barrel. Wall Street is watching oil prices closely, given a shock could have ramifications for the US economy, potentially triggering higher inflation that could spur the Federal Reserve to delay interest-rate cuts. Elsewhere in markets, bitcoin (BTC-USD) retreated, last under the $100,000 level, and gold (GC=F) ticked lower amid a softening in the haven demand that has driven this year's sharp rally. Gold pushed higher with the world in limbo as the US joined Israel's attack on Iran over the weekend. No formal response has been issued by Iran, with wider fallout expected. Spot gold climbed 0.2% to $3,375.04 an ounce taking it to within $125 of its record high as investors sought safe-haven assets in a tumultuous economic situation. Gold then sank 0.5% despite broader haven demand. Bloomberg reports: Read more here. Wall Street is closely watching escalating tensions in the Middle East after President Trump confirmed that the US launched a surprise strike on Iran's nuclear sites late Saturday, marking the country's official entry into the two-week-old conflict. Markets have held mostly steady in the aftermath of the escalation, although US stock futures fell across the board when trading opened Sunday evening. Additionally, bitcoin (BTC-USD) prices, often viewed as a barometer of risk appetite, dropped over 1.6% to trade around $100,500 a coin. WTI crude (CL=F) and Brent (BZ=F) futures jumped, trading near $76 and $79 a barrel, respectively, as uncertainty looms over the potential closure of the critical Strait of Hormuz despite ongoing threats from Iran. The latest surge follows oil's third consecutive week of gains on Friday. "We wouldn't be surprised to see this spark a risk-off reaction in US equities and will be watching the futures closely on Sunday evening and Monday morning," Lori Calvasina, head of US equity strategy research at RBC Capital Markets, wrote in a Sunday evening note to clients. "It has been and remains our belief that the longer and broader the conflict becomes, the more challenging it could be for US equities," Calvasina added. "These escalations come at a tricky time for US equities, as the S&P 500 has looked fairly valued to us (perhaps a bit overvalued) from a fundamental perspective, with more room to run from a sentiment perspective." The analyst said her three main concerns include: first, the risk that rising national security uncertainty could weigh on equity valuations; second, the possibility that renewed geopolitical tensions could stall the recovery in sentiment that began after the early April tariff lows; and third, the potential for a spike in oil prices, which could fuel inflation concerns. In terms of sectors, Energy (XLE) tends to outperform when oils prices rise, while Consumer Discretionary (XLY) and Communication Services (XLC), along with Entertainment, Media, and Interactive Media, tend to lag behind the broader market, Calvasina noted. Citi analyst Stuart Kaiser agreed that sharply higher oil prices remain "the channel for geopolitical risks to impact stock markets," identifying crude prices "well above $80 a barrel" as a critical threshold for concern. Kaiser added that options markets are now pricing in a 10% chance that oil surges 20% over the next month, up from just 2.5% two weeks ago, reflecting mounting tail risks as the conflict deepens. Still, the analyst pointed to resiliency in stocks amid the volatility, saying, "Markets powered through extreme oil volatility and unstable geopolitical headlines to post a risk-on week." Oil prices rose Sunday evening, with investors taking stock of the US entry into the Israel-Iran conflict and how Iran might respond. Much of the focus has turned to Iran's status as a major oil producer and whether it might seek to close the Strait of Hormuz, through which about one-fifth of the world's oil and gas flows. Iran's parliament reportedly pushed for the strait's closure, though it left the ultimate decision up to Iran's top national security body. That may be by design, as Yahoo Finance's Ben Werschkul details: Read more here. Futures tied to the S&P 500 (ES=F) fell 0.6%. (NQ=F) futures dropped 0.7%. Dow Jones Industrial Average futures (YM=F) lost around 0.6%. Oil, both Brent (BZ=F) and WTI, rose over 3%. Gold pushed higher with the world in limbo as the US joined Israel's attack on Iran over the weekend. No formal response has been issued by Iran, with wider fallout expected. Spot gold climbed 0.2% to $3,375.04 an ounce taking it to within $125 of its record high as investors sought safe-haven assets in a tumultuous economic situation. Gold then sank 0.5% despite broader haven demand. Bloomberg reports: Read more here. Wall Street is closely watching escalating tensions in the Middle East after President Trump confirmed that the US launched a surprise strike on Iran's nuclear sites late Saturday, marking the country's official entry into the two-week-old conflict. Markets have held mostly steady in the aftermath of the escalation, although US stock futures fell across the board when trading opened Sunday evening. Additionally, bitcoin (BTC-USD) prices, often viewed as a barometer of risk appetite, dropped over 1.6% to trade around $100,500 a coin. WTI crude (CL=F) and Brent (BZ=F) futures jumped, trading near $76 and $79 a barrel, respectively, as uncertainty looms over the potential closure of the critical Strait of Hormuz despite ongoing threats from Iran. The latest surge follows oil's third consecutive week of gains on Friday. "We wouldn't be surprised to see this spark a risk-off reaction in US equities and will be watching the futures closely on Sunday evening and Monday morning," Lori Calvasina, head of US equity strategy research at RBC Capital Markets, wrote in a Sunday evening note to clients. "It has been and remains our belief that the longer and broader the conflict becomes, the more challenging it could be for US equities," Calvasina added. "These escalations come at a tricky time for US equities, as the S&P 500 has looked fairly valued to us (perhaps a bit overvalued) from a fundamental perspective, with more room to run from a sentiment perspective." The analyst said her three main concerns include: first, the risk that rising national security uncertainty could weigh on equity valuations; second, the possibility that renewed geopolitical tensions could stall the recovery in sentiment that began after the early April tariff lows; and third, the potential for a spike in oil prices, which could fuel inflation concerns. In terms of sectors, Energy (XLE) tends to outperform when oils prices rise, while Consumer Discretionary (XLY) and Communication Services (XLC), along with Entertainment, Media, and Interactive Media, tend to lag behind the broader market, Calvasina noted. Citi analyst Stuart Kaiser agreed that sharply higher oil prices remain "the channel for geopolitical risks to impact stock markets," identifying crude prices "well above $80 a barrel" as a critical threshold for concern. Kaiser added that options markets are now pricing in a 10% chance that oil surges 20% over the next month, up from just 2.5% two weeks ago, reflecting mounting tail risks as the conflict deepens. Still, the analyst pointed to resiliency in stocks amid the volatility, saying, "Markets powered through extreme oil volatility and unstable geopolitical headlines to post a risk-on week." Oil prices rose Sunday evening, with investors taking stock of the US entry into the Israel-Iran conflict and how Iran might respond. Much of the focus has turned to Iran's status as a major oil producer and whether it might seek to close the Strait of Hormuz, through which about one-fifth of the world's oil and gas flows. Iran's parliament reportedly pushed for the strait's closure, though it left the ultimate decision up to Iran's top national security body. That may be by design, as Yahoo Finance's Ben Werschkul details: Read more here. Futures tied to the S&P 500 (ES=F) fell 0.6%. (NQ=F) futures dropped 0.7%. Dow Jones Industrial Average futures (YM=F) lost around 0.6%. Oil, both Brent (BZ=F) and WTI, rose over 3%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
